title: Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
abstract: BACKGROUND
  In order to improve the clinical outcome of patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) not being capable to receive platinum-based chemoradiation, radiotherapy can be intensified by addition of cetuximab, a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR). The radioimmunotherapy with cetuximab is a feasible treatment option showing a favourable toxicity profile. The most frequent side effect of radiotherapy is radiation dermatitis, the most common side effect of treatment with cetuximab is acneiform rash. Incidence and severity of these frequent, often overlapping and sometimes limiting skin reactions, however, are not well explored. A clinical and molecular differentiation between radiogenic skin reactions and skin reactions caused by cetuximab which may correlate with outcome, have never been described before.
  
  
  METHODS
  The HICARE study is a national, multicenter, prospective phase IV study exploring the different types of skin reactions that occur in patients with LASCCHN undergoing radioimmun(chemo)therapy with the EGFR inhibitor cetuximab. 500 patients with LASCCHN will be enrolled in 40 participating sites in Germany. Primary endpoint is the rate of radiation dermatitis NCI CTCAE grade 3 and 4 (v. 4.02). Radioimmunotherapy will be applied according to SmPC, i.e. cetuximab will be administered as loading dose and then weekly during the radiotherapy. Irradiation will be applied as intensity-modulated radiation therapy (IMRT) or 3D-dimensional radiation therapy.
  
  
  CONCLUSIONS
  The HICARE trial is expected to be one of the largest trials ever conducted in head and neck cancer patients. The goal of the HICARE trial is to differentiate skin reactions caused by radiation from those caused by the monoclonal antibody cetuximab, to evaluate the incidence and severity of these skin reactions and to correlate them with outcome parameters. Besides, the translational research program will help to identify and confirm novel peripheral blood based molecular predictors and surrogates for treatment response and resistance.
  
  
  BACKGROUND
  Clinical Trial Identifier, NCT01553032 (clinicaltrials.gov)EudraCT number: 2010-019748-38.
authors.affiliation: Department of Radiation Oncology, University of Heidelberg Medical Center, Im Neuenheimer Feld 400, Heidelberg, 69120, Germany. gregor.habl@med.uni-heidelberg.de
authors.forename: G
authors.initials: G
authors.lastname: Habl
authors.forename: K
authors.initials: K
authors.lastname: Potthoff
authors.forename: M F
authors.initials: MF
authors.lastname: Haefner
authors.forename: A
authors.initials: A
authors.lastname: Abdollahi
authors.forename: J C
authors.initials: JC
authors.lastname: Hassel
authors.forename: E
authors.initials: E
authors.lastname: Boller
authors.forename: M
authors.initials: M
authors.lastname: Indorf
authors.forename: J
authors.initials: J
authors.lastname: Debus
mesh_terms: D006801:Humans; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000628:therapy; D000068818:Cetuximab; D059248:Chemoradiotherapy / Q000009:adverse effects; D006258:Head and Neck Neoplasms / Q000628:therapy; D011855:Radiodermatitis / Q000473:pathology; D011878:Radiotherapy / Q000009:adverse effects; D012107:Research Design; D012871:Skin Diseases / Q000209:etiology; D017327:Clinical Trials, Phase IV as Topic; D015337:Multicenter Studies as Topic
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab